Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin R Dormuth

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Pharmacoepidemiology and Drug Safety|January 9, 2020
A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British ColumbiaColin R Dormuth, Anat Fisher, Greg Carney
Pharmacoeconomics|October 21, 2005
Using policy simulation to predict drug plan expenditure when planning reimbursement changesColin R Dormuth, Sean Burnett, Sebastian Schneeweiss
Gastroenterology Research and Practice|March 13, 2023
Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort StudyAnat Fisher, Jason D Kim, Colin R Dormuth
CMAJ Open|August 1, 2023
Trends in antihypertensive drug utilization in British Columbia, 2004-2019: a descriptive studyJason D Kim, Anat Fisher, Colin R Dormuth
CMAJ Open|February 16, 2022
Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort studyAnat Fisher, Jason D Kim, Colin R Dormuth
Pharmacoepidemiology and Drug Safety|May 29, 2020
Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim reportAnat Fisher, Jason D Kim, Colin R Dormuth
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Trends in health care utilization in British Columbia following public coverage for tiotropiumColin R Dormuth, Richard L Morrow, Greg Carney
Contemporary Clinical Trials|February 3, 2016
Likelihood ratio meta-analysis: New motivation and approach for an old methodColin R Dormuth, Kristian B Filion, Robert W Platt
Drugs & Aging|February 1, 2017
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and SwitchingAnat Fisher, Greg Carney, Ken Bassett, et al.
BMC Medical Research Methodology|February 20, 2016
Head to head comparison of the propensity score and the high-dimensional propensity score matching methodsJason R Guertin, Elham Rahme, Colin R Dormuth, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Pharmacoepidemiology and Drug Safety|January 9, 2020
A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British ColumbiaColin R Dormuth, Anat Fisher, Greg Carney
Pharmacoeconomics|October 21, 2005
Using policy simulation to predict drug plan expenditure when planning reimbursement changesColin R Dormuth, Sean Burnett, Sebastian Schneeweiss
Gastroenterology Research and Practice|March 13, 2023
Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort StudyAnat Fisher, Jason D Kim, Colin R Dormuth
CMAJ Open|August 1, 2023
Trends in antihypertensive drug utilization in British Columbia, 2004-2019: a descriptive studyJason D Kim, Anat Fisher, Colin R Dormuth
CMAJ Open|February 16, 2022
Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort studyAnat Fisher, Jason D Kim, Colin R Dormuth
Pharmacoepidemiology and Drug Safety|May 29, 2020
Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim reportAnat Fisher, Jason D Kim, Colin R Dormuth
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Trends in health care utilization in British Columbia following public coverage for tiotropiumColin R Dormuth, Richard L Morrow, Greg Carney
Contemporary Clinical Trials|February 3, 2016
Likelihood ratio meta-analysis: New motivation and approach for an old methodColin R Dormuth, Kristian B Filion, Robert W Platt
Drugs & Aging|February 1, 2017
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and SwitchingAnat Fisher, Greg Carney, Ken Bassett, et al.
BMC Medical Research Methodology|February 20, 2016
Head to head comparison of the propensity score and the high-dimensional propensity score matching methodsJason R Guertin, Elham Rahme, Colin R Dormuth, et al.
Pageof 9